interferon for COVID-19 - live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 all comers meta-analysis
Cai -FAVIPIRAVIR, 2020 ChiCTR2000029600		NRa	interferon	interferon	COVID 19 all comers	NA	35/45	suggested	suggested 5.5-fold increase in clinical improvement,clinical improvement (14-day)
COVID-19 mild to moderate meta-analysis
Idelsis, 2020 RPCEC00000307		RCT	interferon	interferon	COVID-19 mild to moderate	high	30/33	conclusif	demonstrated 2.3-fold increase in PCR-negative conversion (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 all comers meta-analysis

COVID-19 mild to moderate meta-analysis